Simvastatin and Vimseltinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 4, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Simvastatin
Vimseltinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Vimseltinib (Romvimza) can block a tiny "pump" in your body called BCRP that normally helps move certain drugs out. Simvastatin (Zocor) relies partly on that pump. If it's slowed down, more simvastatin may build up in your body than usual.
More simvastatin can mean a higher chance of side effects, especially muscle aches, soreness, or weakness. This concern is based on how these drugs work rather than real-world reports, so it's a caution, not a certainty. The good news is your care team can manage this by adjusting things or watching you more closely. Please talk with your pharmacist or doctor before changing anything.
Mechanism: Vimseltinib is a theoretical BCRP (ABCG2) inhibitor. Simvastatin is a BCRP substrate, so reduced efflux transport may increase its systemic exposure (higher AUC/Cmax).
Direction: Increased simvastatin exposure, raising risk of dose-dependent myopathy and, rarely, rhabdomyolysis. Neither agent is prodrug-dependent for this pathway.
- Severity: major
- Onset: unspecified
- Evidence: theoretical (mechanistic)
Management: The label advises avoiding concomitant use of vimseltinib with BCRP substrates. If co-use is necessary, statin dose may need to be individualized and patients monitored for muscle symptoms and CK elevations. Confirm with prescriber before any change.
What happens
Increased risk of BCRP substrate exposure
Interaction Deep Dive
Because vimseltinib can raise the exposure of BCRP substrates, taking the two together should be avoided1.
Why it happens (mechanism)
Inhibition of BCRP-mediated efflux transport by vimseltinib
How to manage this interaction
What your care team may do:
- Consider avoiding this combination when possible, since the manufacturer advises against pairing vimseltinib with BCRP substrates like simvastatin.
- If both are needed, adjust and individualize your simvastatin dose and monitor you more closely.
- Watch for muscle-related side effects.
What you should do:
- Keep taking both exactly as prescribed for now.
- Tell your pharmacist or doctor about any new muscle pain, tenderness, weakness, or dark urine.
- Do not start, stop, or change either medicine on your own.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Simvastatin and Vimseltinib together?
Vimseltinib may raise simvastatin levels by blocking the BCRP transporter, increasing the chance of muscle side effects; the label recommends avoiding this combination, so check with your pharmacist or doctor. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Simvastatin and Vimseltinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Simvastatin and Vimseltinib interaction managed?
What your care team may do: Consider avoiding this combination when possible, since the manufacturer advises against pairing vimseltinib with BCRP substrates like simvastatin. If both are needed, adjust and individualize your simvastatin dose and monitor you more closely. Watch for muscle-related side effects. What you should do: Keep taking both exactly as prescribed for now. Tell your pharmacist… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Simvastatin or Vimseltinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ROMVIMZA(TM) oral capsules, vimseltinib oral capsules. Deciphera Pharmaceuticals, LLC (per FDA), Waltham, MA, 2025. DailyMed
Keep reading about Simvastatin
Keep reading about Vimseltinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist